Fund Allocation - The net proceeds from the 2020 subscription amounted to approximately HKD 177,000,000[3] - Approximately HKD 74,571,000 was allocated for settling the outstanding consideration from the acquisition of Baorunlai Property Holdings Group Limited[3] - The remaining balance of approximately HKD 102,429,000 was designated for general working capital[3] Utilization of Proceeds - As of December 31, 2020, approximately HKD 13,920,000 of the net proceeds was used for settling the outstanding consideration[4] - The remaining unutilized balance for settling the consideration is approximately HKD 60,651,000, which is still designated for that purpose[4] - The company expects to complete the settlement of the remaining consideration by 2026 or earlier[4]

Core Points - HUTCHMED will announce its interim results for the six months ended June 30, 2025, on August 7, 2025, at 7:00 am EDT [1] - The company will host two webcast presentations for analysts and investors to discuss the interim results, with the English session at 8:00 am EDT and the Chinese session at 8:30 am HKT on August 8, 2025 [2] - Both webcasts will be available live on the company website, with a replay accessible shortly after the events [3] Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [4] - The company has successfully marketed its first three medicines in China, with the first also approved globally, including in the US, Europe, and Japan [4]

Group 1 - The core viewpoint of the articles highlights the increasing recognition of gold as a valuable investment, attracting a new generation of investors, particularly those born after 1995 [1][2] - The data from JD Finance indicates that investors from the post-90s generation now account for over 50% of gold investors, with Generation Z emerging as a key demographic in gold investment [1] - Investment characteristics of this demographic show a preference for "light entry and flexible operation," with over 60% of transactions involving accumulation gold products, primarily occurring during evening hours [1] Group 2 - JD Finance has established a comprehensive gold trading platform that includes physical gold, accumulation gold, gold ETFs, and gold recycling, emphasizing gold as an important asset allocation dimension [2] - The company plans to upgrade its platform in three main areas: enhancing investor education, improving the product system by collaborating with banks and fund companies, and refining professional service systems for gold investment [2] - The geographical distribution of gold consumption shows Guangdong, Jiangsu, and Zhejiang as the top three regions, with cultural factors influencing their positions [1]

Pipeline and Approvals - Ultragenyx expects Phase 3 data readout for UX143 for Osteogenesis Imperfecta (OI) in 2025[21, 32] - Ultragenyx anticipates completing Phase 3 enrollment for GTX-102 for Angelman Syndrome (AS) in the second half of 2025[46, 49] - The company has a PDUFA date of August 18, 2025, for UX111 for Sanfilippo syndrome (MPS IIIA), with a potential commercial launch in the second half of 2025[63, 67] - Ultragenyx expects to submit a BLA for DTX401 for Glycogen Storage Disease Type Ia (GSDIa) in mid-2025, with a potential launch in 2026[78, 80] Financial Performance and Projections - Ultragenyx projects total revenue to grow by 14-20% in 2025, reaching $640-670 million[93, 95] - The company anticipates Crysvita revenue to be $460-480 million in 2025, representing a 12-17% increase[95] - Dojolvi revenue is projected to be $90-100 million in 2025, a 2-13% increase[95] - Ultragenyx aims to achieve full-year GAAP profitability in 2027, driven by revenue growth, new product launches, and expense management[2, 96, 99] Clinical Trial Results - Phase 2 data for UX143 in OI showed a 67% reduction in annualized fracture rate (AFR) [33] - Phase 3 data for DTX401 in GSDIa demonstrated a statistically significant 41% reduction in daily cornstarch intake at Week 48 (p < 0.0001)[83] - UX111 for MPS IIIA showed >80% of participants reduced CSF HS by 50% in efficacy set[71]

一、行情回顾 市场全天震荡反弹，创业板指领涨。算力硬件股再度大涨，PCB等方向领涨，中京电子、博敏电子、金安国纪等涨停。创新药概念延续强势，塞力医疗、未 名医药、神州细胞等十余股封板。固态电池板块午后拉升，大东南、洪田股份、中一科技涨停。下跌方面，海洋经济概念股展开调整，克莱特跌超10%。个 股涨多跌少，沪深京三市近3300股飘红，今日成交1.33万亿。 二、当日热点 1.PCB板 PCB板今日大涨，中京电子再度涨停，博敏电子、金安国纪等多股涨停。胜宏科技大涨6%，再创历史新高。 | 股票名称 | | 最新价 ◆ | 涨跌幅 = | 涨停时间 ◆ | 换手率 = | 流通市值⇒ | | | --- | --- | --- | --- | --- | --- | --- | --- | | 中京电子 | 12天7板 | 15.60 | +10.01% | 13:53:33 | 38.49% | 90.72亿 | 公司主 | | 002579.SZ | | | | | | | 形机器 | | | | | | | | | 1、公 开拓国 | | 博敏电子 | 3天2板 | 10.41 | +10.04% | 09: ...

深莞惠三市同属东江流域，地缘相接、水脉相连，做好生态环境保护离不开协调合作。第一财经记者注 意到，为了构建"美美与共"的协调发展格局，《规划》明确提出，要打破传统行政壁垒，实现一体化制 度创新，并设置专章对协同开展美丽城市、美丽县城、美丽乡村、美丽河湖、美丽海湾建设等方面任务 重点部署。 在三市政府统筹指导和都市圈联席工作机制下，三市打破"一亩三分地"思维，求同存异，由深圳市生态 环境局牵头，联合东莞、惠州市生态环境局，首次构建统一编制、联合报批、共同实施的跨区域生态环 境规划管理体制，健全常态化协商、政策协同、跨界共治、红利共享等体制机制，推动构建深圳都市圈 生态环境保护一体化格局。 《规划》旨在实现"1+1+1＞3"的生态共赢愿景 近日，深圳、东莞、惠州三市生态环境部门联合印发《深圳都市圈生态环境保护规划（2025—2030 年）》（下称《规划》）。这是广东省首个都市圈生态环境保护专项规划，也是深圳都市圈"1+N"规划 政策体系中的首个专项规划。 《规划》提出打造珠江流域环境协同治理典范、美丽都市圈建设示范样板、全球城市群绿色发展标杆三 大战略定位，构建深圳都市圈生态环境共保共治体系，着力解决都市圈跨区域 ...

南方报业传媒集团（南方日报社）全面启动系统性变革。围绕社会热点、产经重点、国际爆点、文旅视 点和民生关注点，南方报业将重点打造20个新媒体IP，"南都即时"位列其中。 "南都即时"系荣获广东新闻奖一等奖的新媒体品牌栏目，并曾有作品荣获中国新闻奖等多个省部级奖 项，由南方都市报深度调查部运营。"南都即时"以"快"为特色，围绕各类突发事件、社会热点，持续推 出动态、视频、特稿、专题、调查、快评等融媒体产品。 变革不止，创新不停！"南都即时"正通过升级原创新闻产品矩阵，力争通过提供事实增量、强化价值输 出、塑造南都议题，追求舆论场上的独家快讯"首发"、新闻延展"首追"、深度调查"首推"、对外传 播"首见"。 独家快讯"首发" 强化独家新闻采写，持续提供事实增量。南都即时以"快"为核心竞争力，多年来持续从报道热点事件出 发，赢得海内外舆论场首发先机，目前已发稿超46700篇，全渠道分发流量已突破145亿。例如，今年5 月，哈佛大学被禁止招收国际学生持续引发全球关注，南都即时快速跟进，独家采访获得哈佛大学回 应："美国国土安全部相关行为堪称任意武断的行为典范"，抨击美国政府政策混乱，发出独特声音。 建构南都特色话题，理 ...

欣强电子的主营业务是印制电路板的研发、生产和销售。公司印制电路板产品定位于中高端市场，以八层及以上高端PCB为主， 产品均价超过2,000元/ 平方米，处于行业第一梯队。 据招股书，2022年-2024年，欣强电子实现营收分别为8.69亿元、10亿元、9.99亿元；归母净利润分别为8498.39万元、1.32亿元、1.68亿元。 瑞财经 吴文婷 近日，欣强电子（清远）股份有限公司（以下简称"欣强电子"）创业板IPO申请获受理，保荐机构为民生证券股份有限公司，保荐代表人 为曾文强、帖晓东，会计师事务所为普华永道中天会计师事务所（特殊普通合伙）。 | 项目 | 2024年12月 31 | 2023年12月31 | 2022年12月 31 | | --- | --- | --- | --- | | | 日/2024 年度 | 日/2023 年度 | 日/2022 年度 | | 资产总额(万元) | 111,113.68 | 99,579.93 | 98,929.04 | | 归属于母公司的所有者权益(万元) | 83,713.06 | 66.714.59 | 57.975.25 | | 资产负债率(母公司) | 2 ...

瑞财经 吴文婷7月2日晚，时隔三个月，小米创始人、董事长兼CEO雷军佩戴最新发布小米AI眼镜，开 启返场直播，其介绍了小米YU7的订单、交付情况。 雷军在直播中回应了关于YU7大定数据的质疑："当时发布了大定数据后，我们受到了大量的质疑，有 人说是可退的。所谓的'犹豫期'看上去有点故弄玄虚，其实这是所有车厂都在采用的方式。因此，我们 大定量的统计口径和所有车企都是一样的。" 据了解，6月26日，小米首款SUV车型YU7正式发布上市，起售价25.35万元，该款车型上市即取得亮 眼"战报"。小米汽车官微称，3分钟，小米YU7大定突破20万辆。1小时，大定突破28.9万辆。开售18小 时，小米YU7锁单量突破24万辆。 ml 小米汽车 窗 25-6-27 16:11 发布于 北京 来自 Xiaomi 14 Ultra 已编辑 十关注 开售18小时, #小米YU7# 锁单量已突破240000台, 真诚感谢每一位朋友的支持。 (mg EE 22416 同时，其还透露了YU7的用户画像。小米YU7车主的平均年龄约为33岁，比小米SU7用户大三岁；女性 车主的比例为30%，比小米SU7的首销期大概高出4.5%。在小米YU7 ...

北京新房市场点状高温，二手房成交增两成。 六个楼盘销售额超40亿、总价1000万～2000万的新房成交套数增九成，今年上半年，北京楼市平稳收官 之余，部分新房楼盘"点状"繁荣、看点颇多。 二手房市场成交规模也明显上扬，上半年，北京二手商品住宅累计网签量达到88575套，同比增长 18%，网签规模高于过去2022至2024年的同期水平。 千万总价的新房成交火热 今年上半年，北京新房市场企稳收官。中指数据显示，期内北京新建商品住宅累计成交267万平方米， 同比增长3%，基本稳住了成交盘面。 从月度趋势看，上半年北京楼市经历了数次增长期，3月出现"小阳春"行情，当月新房成交面积同比增 长近五成；二季度市场延续修复态势，同比增长15%。 朝阳、昌平、海淀、顺义、丰台，是北京新房成交的"主力军"，新房销售面积均超过25万平方米；项目 层面，上半年共有6个楼盘销售额超40亿元，其中海淀4个、朝阳2个，区位配套好的高品质改善楼盘去 化较好。 相较于整体成交数据，上半年北京的高端楼盘更加亮眼。 据中指数据显示，上半年北京总价在1000万～2000万区间的新房，成交量保持较快增长，成交套数同比 增长近9成，市场占比从2024年 ...